<DOC>
	<DOCNO>NCT00012142</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Randomized phase II trial determine effectiveness CCI-779 treat patient progressive prostate cancer .</brief_summary>
	<brief_title>CCI-779 Treating Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety CCI-779 patient androgen-independent prostate cancer . II . Determine effect CCI-779 prostate-specific antigen level patient . III . Assess pharmacokinetic parameter CCI-779 patient . IV . Assess possible pharmacodynamic relationship CCI-779 clinical response patient . V. Determine impact CCI-779 quality life patient . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients randomize 1 4 arm . Arm I : Patients receive low-dose CCI-779 IV 30 minute weekly . Arm II : Patients receive high-dose CCI-779 IV 30 minute weekly . Arm III : Patients receive low-dose placebo IV 30 minute weekly . Arm IV : Patients receive high-dose placebo IV 30 minute weekly . Treatment continue absence disease progression unacceptable toxicity . Patients develop progressive disease receive placebo may cross equivalent dose CCI-779 . Quality life assess baseline ; week 4 , 8 , 12 , 24 , 36 ; final/cross-over visit . Patients follow every 3 month . PROJECTED ACCRUAL : Approximately 150 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm asymptomatic , progressive , metastatic adenocarcinoma prostate Progressive disease define increase prostatespecific antigen ( PSA ) level 2 measurement least 2 week apart PSA great 5 ng/mL Continued medical mean gonadal ablation ( e.g. , luteinizing hormone release hormone ( LHRH ) ) require No known CNS metastases unless previously treat surgery radiotherapy stable , asymptomatic , require steroid anticonvulsant PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 6 month Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 8.5 g/Dl Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) AST great 3 time ULN ( great 5 time ULN liver metastasis present ) Serum cholesterol great 350 mg/Dl Triglycerides great 300 mg/Dl Renal : Creatinine great 1.5 time ULN Cardiovascular : No unstable angina lifethreatening ventricular arrhythmia require maintenance therapy No myocardial infarction within past 6 month Other : No malignancy past 5 year basal cell squamous cell skin cancer HIV negative No active infection Not immunocompromised No major illness would preclude study Fertile patient must use effective contraception 3 month study PRIOR CONCURRENT THERAPY : Biologic therapy : Concurrent epoetin alfa allow Chemotherapy : No prior cytotoxic chemotherapy prostate cancer No concurrent chemotherapy Endocrine therapy : See Disease Characteristics At least 6 week since prior antiandrogen therapy At least 4 week since prior hormonal therapy ( 6 week antiandrogens ) prostate cancer continue LHRH agonist No concurrent systemic corticosteroid No concurrent anticancer hormonal therapy Radiotherapy : At least 3 week since prior radiotherapy No prior palliative radiotherapy one site No prior strontium chloride Sr 89 samarium Sm 153 lexidronam pentasodium No concurrent radiotherapy Surgery : At least 3 week since prior surgery Other : At least 4 week since prior investigational agent No concurrent immunosuppressive agent No concurrent investigational agent No concurrent enzymeinducing anticonvulsant ( carbamazepine , phenobarbital , phenytoin ) , ketoconazole , diltiazem , rifampin , terfenadine , cisapride , astemizole , pimozide No concurrent megestrol acetate appetite Concurrent bisphosphonates allow</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2002</verification_date>
	<keyword>stage IV prostate cancer</keyword>
</DOC>